Ardelyx, Inc. · NASDAQ:ARDX
Ardelyx — Q3 2026 Earnings Presentation
15 slides from Ardelyx's earnings presentation, Nov 3, 2026
Slide 1: Q3 2026 Earnings Call
This presentation is intended for investor purposes only and is not intended for promotional purposes. 1Q3 2026 Earnings Q3 2026 Earnings Call November 3, 2026
Slide 2: Participants
Participants Mike Raab President & Chief Executive Officer Sue Hohenleitner, CPA, CMA Chief Financial Officer 2This presentation is intended for investor purposes only and is not intended for promotional purposes. Q3 2026 Earnings
Slide 3: Forward-Looking Statements
This presentation is intended for investor purposes only and is not intended for promotional purposes. 3Q3 2026 Earnings Forward-Looking Statements To the extent that statements contained in this presentation and the accompanying oral presentation are not descriptions of historical facts regarding A
Slide 4: Building a Great Company
This presentation is intended for investor purposes only and is not intended for promotional purposes. 4Q3 2026 Earnings Building a Great Company A Commercial Stage, Patient-Centric Biopharmaceutical Company with Multiple Value Drivers First-in-Class Products Two FDA approved, first- in-class produc
Slide 5: Focused on Executing Our 2026 Strategic Priorities
This presentation is intended for investor purposes only and is not intended for promotional purposes. 5Q3 2026 Earnings Significantly grow IBSRELA demand Maintain XPHOZAH momentum Build and expand our pipeline of innovative medicines Continue delivering strong financial performance Focused on Execu
Slide 6: Strong Commercial Performance Strategy to Grow IBSRELA
This presentation is intended for investor purposes only and is not intended for promotional purposes. 6Q3 2026 Earnings Strong Commercial Performance Strategy to Grow IBSRELA Q3 2026 Revenue $96.3M 23% Demand at an All-Time High as Growth Initiatives Take Hold Growth Year-over-Year Number of total
Slide 7: IBSRELA DTC Launched To Drive Consumer Awareness and Engagement
This presentation is intended for investor purposes only and is not intended for promotional purposes. 7Q3 2026 Earnings IBSRELA DTC Launched To Drive Consumer Awareness and Engagement *Animatic Testing March 2026 • In testing phase, 91% of patients said they would ask their doctor if IBSRELA was ri
Slide 8: IBSRELA Benefits Address Large IBS-C Market with Significant Unmet Need
This presentation is intended for investor purposes only and is not intended for promotional purposes. 8Q3 2026 Earnings Re tr os pe ct iv e ob se rv at io na l a na ly sis w ith ou t a c om pa ra to r g ro up . C ha ng es in HC RU c an no t b e at tr ib ut ed so le ly to te na pa no r i ni tia tio
Slide 9: Hyperphosphatemia Market in Need of Innovation
This presentation is intended for investor purposes only and is not intended for promotional purposes. 9Q3 2026 Earnings Hyperphosphatemia Market in Need of Innovation 70% of patients on binder are unable to consistently achieve and maintain target phosphorus levels2 >550,000 patients with CKD on di
Slide 10: ACCEL P3 Trial Fully Enrolled: Tenapanor for CIC
This presentation is intended for investor purposes only and is not intended for promotional purposes. 10Q3 2026 Earnings ACCEL P3 Trial Fully Enrolled: Evaluating Safety and Efficacy of Tenapanor for CIC 26-week multi-center, randomized, double-blinded, placebo-controlled study The need is real –
Slide 11: Third Quarter 2026 Highlights
This presentation is intended for investor purposes only and is not intended for promotional purposes. 11Q3 2026 Earnings Third Quarter 2026 Highlights Turning Growth into Financial ProgressIBSRELA Driving Growth Net loss narrowed to ($0.7M) Reaffirming Full-Year 2026 Guidance +23% YoY Revenue growt
Slide 12: Third Quarter 2026 Financial Highlights
This presentation is intended for investor purposes only and is not intended for promotional purposes. 12Q3 2026 Earnings Third Quarter 2026 Financial Highlights 1. Includes R&D and SG&A expenses 2. Includes total cash, cash equivalents and short-term investments Percentages have been calculated usi
Slide 13: Corporate Outlook FY 2026
This presentation is intended for investor purposes only and is not intended for promotional purposes. 13Q3 2026 Earnings Corporate Outlook FY 2026 Financial Guidance $ in millions Guidance IBSRELA Revenue $350 - $370 XPHOZAH Revenue $110 - $120 Operating Expenses Below $500 Represents annual growth
Slide 14: Capital Allocation Strategy
This presentation is intended for investor purposes only and is not intended for promotional purposes. 14Q3 2026 Earnings Capital Allocation Strategy Looking ahead: as IBSRELA scales toward $1B and we approach profitability, capital allocation priorities may evolve. Disciplined investment for durabl
Slide 15: Thank You
This presentation is intended for investor purposes only and is not intended for promotional purposes. 15Q3 2026 Earnings Thank You